PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer

What’s known on the subject? and What does the study add?

[1]  R. Shah,et al.  Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression , 2009, Modern Pathology.

[2]  F. Saad,et al.  PTEN genomic deletion is associated with p‐Akt and AR signalling in poorer outcome, hormone refractory prostate cancer , 2009, The Journal of pathology.

[3]  J. Squire.  TMPRSS2-ERG and PTEN loss in prostate cancer , 2009, Nature Genetics.

[4]  C. Sander,et al.  Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis , 2009, Nature Genetics.

[5]  M. Rubin,et al.  INTEGRATION OF ERG GENE MAPPING AND GENE‐EXPRESSION PROFILING IDENTIFIES DISTINCT CATEGORIES OF HUMAN PROSTATE CANCER , 2009, BJU international.

[6]  Pier Paolo Pandolfi,et al.  Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate , 2009, Nature Genetics.

[7]  D. Dearnaley,et al.  Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. , 2009, Cancer research.

[8]  M. Gerstein,et al.  Distinct genomic aberrations associated with ERG rearranged prostate cancer , 2009, Genes, chromosomes & cancer.

[9]  G. Jenster,et al.  Overexpression of Prostate-Specific TMPRSS2(exon 0)-ERG Fusion Transcripts Corresponds with Favorable Prognosis of Prostate Cancer , 2009, Clinical Cancer Research.

[10]  R. Vollmer,et al.  Fascin Regulates Prostate Cancer Cell Invasion and Is Associated with Metastasis and Biochemical Failure in Prostate Cancer , 2009, Clinical Cancer Research.

[11]  C. LaFargue,et al.  TMPRSS2-ERG fusion is frequently observed in gleason pattern 3 prostate cancer in a Canadian cohort , 2009, Cancer biology & therapy.

[12]  O. Ludkovski,et al.  Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome , 2008, Modern Pathology.

[13]  K. Nielsen,et al.  Is PTEN loss associated with clinical outcome measures in human prostate cancer? , 2008, British Journal of Cancer.

[14]  P. Abel,et al.  Predictive value of PTEN and AR coexpression of sustained responsiveness to hormonal therapy in prostate cancer--a pilot study. , 2008, Neoplasia.

[15]  M. Gleave,et al.  Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer , 2008, BMC Cancer.

[16]  T. Golub,et al.  Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. , 2008, Journal of the National Cancer Institute.

[17]  T. Tammela,et al.  TMPRSS2:ERG Fusion Identifies a Subgroup of Prostate Cancers with a Favorable Prognosis , 2008, Clinical Cancer Research.

[18]  M. Loda,et al.  Characterization of TMPRSS2-ERG Fusion High-Grade Prostatic Intraepithelial Neoplasia and Potential Clinical Implications , 2008, Clinical Cancer Research.

[19]  R. Shah,et al.  Role of the TMPRSS2-ERG gene fusion in prostate cancer. , 2008, Neoplasia.

[20]  J Cuzick,et al.  Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer , 2008, Oncogene.

[21]  J. Brooks,et al.  Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. , 2007, Cancer research.

[22]  J. Squire,et al.  FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome , 2007, British Journal of Cancer.

[23]  S. Dhanasekaran,et al.  Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer , 2007, Nature.

[24]  M. Shen,et al.  Pten inactivation and the emergence of androgen-independent prostate cancer. , 2007, Cancer research.

[25]  Yao-Tseng Chen,et al.  Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues , 2007, Modern Pathology.

[26]  Y Pawitan,et al.  TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort , 2007, Oncogene.

[27]  J. Damber,et al.  Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer. , 2007, Oncology reports.

[28]  J. Mossong,et al.  Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis , 2007, International journal of cancer.

[29]  S. Leung,et al.  Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers , 2007, Journal of Clinical Pathology.

[30]  P. Pandolfi,et al.  Essential Role for Nuclear PTEN in Maintaining Chromosomal Integrity , 2007, Cell.

[31]  L. Klotz,et al.  Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression , 2007, Cancer biology & therapy.

[32]  M. Rubin,et al.  TMPRSS2-ERG Fusion Prostate Cancer: An Early Molecular Event Associated With Invasion , 2006, The American journal of surgical pathology.

[33]  Michael Ittmann,et al.  Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. , 2006, Cancer research.

[34]  J. Tchinda,et al.  TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. , 2006, Cancer research.

[35]  Paulo A. S. Nuin,et al.  Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. , 2006, Cancer genetics and cytogenetics.

[36]  J. Tchinda,et al.  Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer , 2005, Science.

[37]  William R Sellers,et al.  The biology and clinical relevance of the PTEN tumor suppressor pathway. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  K. H. Gulkesen,et al.  The assessment of PTEN tumor suppressor gene in combination with Gleason scoring and serum PSA to evaluate progression of prostate carcinoma. , 2004, Urologic oncology.

[39]  K. Failing,et al.  Expression of PTEN in malignant and non‐malignant human prostate tissues: comparison with p27 protein expression , 2004, The Journal of pathology.

[40]  D. Leroith,et al.  PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells , 2004, Oncogene.

[41]  D. Tindall,et al.  The role of PTEN in the progression and survival of prostate cancer. , 2003, Minerva endocrinologica.

[42]  O. Halvorsen,et al.  Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[43]  J. Gutkind,et al.  Loss of PTEN expression leading to high Akt activation in human multiple myelomas. , 2000, Blood.

[44]  J. C. Law,et al.  PTEN and prostate cancer. , 1998, Journal of medical genetics.

[45]  M. Ittmann,et al.  Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  T. Tammela,et al.  TCEB1 promotes invasion of prostate cancer cells , 2009, International journal of cancer.

[47]  M. Loda,et al.  Characterization of TMPRSS 2-ERG Fusion High-Grade Prostatic Intraepithelial Neoplasia and Potential Clinical Implications , 2008 .